CN102041270A - 胃癌靶向DEC1基因的siRNAs表达载体的构建、筛选及其用途 - Google Patents
胃癌靶向DEC1基因的siRNAs表达载体的构建、筛选及其用途 Download PDFInfo
- Publication number
- CN102041270A CN102041270A CN 201010288486 CN201010288486A CN102041270A CN 102041270 A CN102041270 A CN 102041270A CN 201010288486 CN201010288486 CN 201010288486 CN 201010288486 A CN201010288486 A CN 201010288486A CN 102041270 A CN102041270 A CN 102041270A
- Authority
- CN
- China
- Prior art keywords
- dec1
- plasmid
- gene
- expression
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 36
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 28
- 239000013604 expression vector Substances 0.000 title claims abstract description 24
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 18
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 18
- 101000765038 Homo sapiens Class E basic helix-loop-helix protein 40 Proteins 0.000 title abstract description 69
- 102100026191 Class E basic helix-loop-helix protein 40 Human genes 0.000 title abstract description 68
- 238000012216 screening Methods 0.000 title abstract description 8
- 230000002452 interceptive effect Effects 0.000 title abstract description 3
- 101150084062 RAN gene Proteins 0.000 title abstract 2
- 238000010276 construction Methods 0.000 title abstract 2
- 230000014509 gene expression Effects 0.000 claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 37
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims abstract description 12
- 230000009368 gene silencing by RNA Effects 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000013612 plasmid Substances 0.000 claims description 71
- 108091034117 Oligonucleotide Proteins 0.000 claims description 40
- 108020004414 DNA Proteins 0.000 claims description 25
- 101100009195 Cochliobolus heterostrophus (strain C4 / ATCC 48331 / race T) DEC1 gene Proteins 0.000 claims description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 20
- 239000004055 small Interfering RNA Substances 0.000 claims description 15
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 14
- 238000013461 design Methods 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- 238000010367 cloning Methods 0.000 claims description 13
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 12
- 238000011156 evaluation Methods 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 201000000498 stomach carcinoma Diseases 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 238000011144 upstream manufacturing Methods 0.000 claims description 9
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 8
- 239000013599 cloning vector Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000002441 reversible effect Effects 0.000 claims description 7
- 230000000692 anti-sense effect Effects 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 239000013600 plasmid vector Substances 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- 108700026244 Open Reading Frames Proteins 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 239000013613 expression plasmid Substances 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 4
- 210000004962 mammalian cell Anatomy 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001890 transfection Methods 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000007788 liquid Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 15
- 238000003757 reverse transcription PCR Methods 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000002502 liposome Substances 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 238000001962 electrophoresis Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000006180 TBST buffer Substances 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 5
- 108090000364 Ligases Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000002934 lysing effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 2
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000009871 tenuigenin Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000004091 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 101710130550 Class E basic helix-loop-helix protein 40 Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
DEC1-siRNA1 | DEC1-siRNA2 | 空载体对照 | |
质粒浓度(μg/μl) | 1.32 | 1.20 | 1.34 |
A260/A280 | 1.860 | 1.839 | 1.823 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102884865A CN102041270B (zh) | 2010-09-21 | 2010-09-21 | 胃癌靶向DEC1基因的siRNAs表达载体的构建、筛选及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102884865A CN102041270B (zh) | 2010-09-21 | 2010-09-21 | 胃癌靶向DEC1基因的siRNAs表达载体的构建、筛选及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102041270A true CN102041270A (zh) | 2011-05-04 |
CN102041270B CN102041270B (zh) | 2012-07-18 |
Family
ID=43907818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102884865A Expired - Fee Related CN102041270B (zh) | 2010-09-21 | 2010-09-21 | 胃癌靶向DEC1基因的siRNAs表达载体的构建、筛选及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102041270B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107058390A (zh) * | 2017-01-17 | 2017-08-18 | 上海交通大学医学院附属第九人民医院 | 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552876A (zh) * | 2003-12-18 | 2004-12-08 | 济南市中心医院 | 靶向肝癌AFP基因的siRNAs表达载体及其构建方法与用途 |
CN1940074A (zh) * | 2006-08-07 | 2007-04-04 | 汪运山 | 胃癌靶向AFP基因的siRNAs表达载体的构建、筛选及其用途 |
-
2010
- 2010-09-21 CN CN2010102884865A patent/CN102041270B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552876A (zh) * | 2003-12-18 | 2004-12-08 | 济南市中心医院 | 靶向肝癌AFP基因的siRNAs表达载体及其构建方法与用途 |
CN1940074A (zh) * | 2006-08-07 | 2007-04-04 | 汪运山 | 胃癌靶向AFP基因的siRNAs表达载体的构建、筛选及其用途 |
Non-Patent Citations (1)
Title |
---|
《中华肿瘤防治杂志》 20090716 王敏,郑燕,郏雁飞,李彬彬,汪运山, 胃癌组织转录调节因子DEC1表达及其临床意义的研究 1002-1005 1 第16卷, 第13期 2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107058390A (zh) * | 2017-01-17 | 2017-08-18 | 上海交通大学医学院附属第九人民医院 | 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102041270B (zh) | 2012-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jiang et al. | MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo | |
Li et al. | Suppression of CX43 expression by miR-20a in the progression of human prostate cancer | |
Li et al. | MiR-661 inhibits glioma cell proliferation, migration and invasion by targeting hTERT | |
CN102304538B (zh) | 胃癌靶向STAT3基因的siRNAs表达载体 | |
Liu et al. | MiR-486-5p inhibits the proliferation of leukemia cells and induces apoptosis through targeting FOXO1 | |
Qiao et al. | Microarray analysis of circRNAs expression profile in gliomas reveals that circ_0037655 could promote glioma progression by regulating miR-214/PI3K signaling | |
Tian et al. | Klf4 inhibits tumor growth and metastasis by targeting microRNA-31 in human hepatocellular carcinoma | |
Taddei et al. | Stromal‐induced downregulation of miR‐1247 promotes prostate cancer malignancy | |
Ye et al. | Induced MiR-1249 expression by aberrant activation of Hedegehog signaling pathway in hepatocellular carcinoma | |
CN103233009B (zh) | 降低锌指蛋白ctcf表达的物质在制备治疗白血病药物中的应用 | |
Li et al. | MicroRNA hsa-miR-150-5p inhibits nasopharyngeal carcinogenesis by suppressing PYCR1 (pyrroline-5-carboxylate reductase 1) | |
Mackedenski et al. | Characterizing the interaction between insulin-like growth factor 2 mRNA-binding protein 1 (IMP1) and KRAS expression | |
CN101338321B (zh) | 胃癌靶向FUT3基因的miRNAs表达载体的构建、筛选及其用途 | |
Su et al. | LncRNA MALAT1 promotes glioma cell growth through sponge miR-613 | |
EP1599586B9 (en) | Rna-interference for znfn3a1-gene as a method for inhibiting cancer cell growth | |
CN101353656B (zh) | 抑制表皮生长因子受体基因表达的siRNA及其应用 | |
CN102041270B (zh) | 胃癌靶向DEC1基因的siRNAs表达载体的构建、筛选及其用途 | |
CN101705227B (zh) | 抑制人AP-2alpha基因表达的siRNA在抗宫颈癌药物制备中的应用 | |
CN102676518B (zh) | 一种新型抗肿瘤amiRNA序列及其应用 | |
CN107541514B (zh) | 特异性抑制COL12A1基因表达的siRNA及其重组载体和应用 | |
CN100374573C (zh) | 一种可稳定表达VEGF shRNA的载体pCD-VEGF | |
CN107354157B (zh) | 特异性抑制LAMB1基因表达的siRNA及其重组载体和应用 | |
CN103031334A (zh) | 抑制STAT3 和AFP 基因表达的双靶标siRNA 真核表达质粒及其用途 | |
CN103343125A (zh) | 一种抑制结肠癌细胞PRPS2表达的shRNA及其载体的构建和应用 | |
CN102174514B (zh) | 一种抑制Hmga2基因表达的双链siRNA及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JI NAN CELL BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: WANG YUNSHAN Effective date: 20120525 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Henghuan Inventor after: Jia Yanfei Inventor after: Zheng Yan Inventor after: Ma Xiaoli Inventor after: Xiao Dongjie Inventor after: Sun Shanhui Inventor after: Wei Yan Inventor after: Wang Yunshan Inventor after: Cai Pingping Inventor before: Wang Yunshan Inventor before: Jia Yanfei Inventor before: Zheng Yan Inventor before: Ma Xiaoli Inventor before: Xiao Dongjie Inventor before: Sun Shanhui Inventor before: Wei Yan |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250013 JINAN, SHANDONG PROVINCE TO: 250101 JINAN, SHANDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: WANG YUNSHAN JIA YANFEI ZHENG YAN MA XIAOLI XIAO DONGJIE SUN SHANHUI WEI YAN TO: WANG HENGHUAN JIA YANFEI ZHENG YAN MA XIAOLI XIAO DONGJIE SUN SHANHUI WEI YAN WANG YUNSHAN CAI PINGPING |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120525 Address after: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 B201 Applicant after: Jinan Cell Bio-Technology Co., Ltd. Address before: 250013 central laboratory, No. 105, Jiefang Road, Lixia District, Shandong, Ji'nan Applicant before: Wang Yunshan |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120718 Termination date: 20140921 |
|
EXPY | Termination of patent right or utility model |